MedTrace Logo

Safety and Pharmacology Study of BMS-866949

NCT01124344 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2012-03-27

No results posted yet for this study

Summary

The main purpose of this study is to determine whether multiple doses.of BMS-886949 are safe and tolerable

Conditions

Interventions

DRUG

Placebo

Oral Solution, Oral, 0 mg, Once Daily, 14 days

DRUG

BMS-866949

Oral Solution, Oral, 3 mg, Once Daily, 14 days

DRUG

BMS-866949

Oral Solution, Oral, 10 mg, Once Daily, 14 days

DRUG

BMS-866949

Oral Solution, Oral, 30 mg, Once Daily, 14 days

DRUG

BMS-866949

Oral Solution, Oral, 45 mg, Once Daily, 14 days

DRUG

BMS-866949

Oral Solution, Oral, 60 mg, Once Daily, 14 days

DRUG

BMS-866949

Oral Solution, Oral, 90 mg, Once Daily, 14 days

DRUG

BMS-866949

Oral Solution, Oral, 3-60 mg, Once Daily, 14 days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01124344 on ClinicalTrials.gov